Introduction
============

Many frail older people spend their final years of life in aged care facilities. In Aus-tralia, the proportion of older people living in care accommodation increases with age from 2% of people aged 65--74 years to 6% of people aged 75--84 years and 26% of people aged 85 years and over.[@b1-cia-10-1043] Those living in care homes often take more medications than noninstitutionalized elderly, and the risk of morbidity as a result of medication is high.[@b2-cia-10-1043] Also, the incidence of adverse drug events increases with the number of medications prescribed.[@b3-cia-10-1043] Residential aged care facilities (RACFs) in Australia are institutions in which prescribing of high-risk medication such as antipsychotics, potent analgesics, and sedatives is high, with between 25% and 30% of patients receiving such medication.[@b4-cia-10-1043]--[@b6-cia-10-1043] Ensuring high-quality care and appropriate medication use for these residents is challenging given their frailty, complex disabilities, and multiple chronic conditions.[@b7-cia-10-1043]

Despite the growing body of literature indicating that medication errors and potentially inappropriate medications are important causes of morbidity and mortality, evidence for effective interventions and strategies to improve the pharmacological management of patients is still limited.[@b8-cia-10-1043] Well-organized approaches are needed to provide specialist advice in nursing homes to ensure quality medical care. Practice models that include a pharmacist as part of the multidisciplinary team represent best practice in inpatient, ambulatory, and community settings, and in care transitions between settings.[@b9-cia-10-1043] Geriatrician-led case conference reviews and comprehensive geriatric assessments (CGAs) have been shown to be effective in reducing potentially inappropriate medications use and improved suboptimal prescribing.[@b7-cia-10-1043],[@b10-cia-10-1043] Although access to geriatric services in Australian RACFs is limited, expert advice is increasingly provided by videoconferencing (VC).

In the model offered in relation to this study, a specialist geriatrician provides a comprehensive assessment of the patient and input into care plans via VC. Geriatricians make recommendation about patients' medications, perhaps advising that some medications are stopped or others commenced. We designed this study to examine whether VC-mediated geriatric assessment resulted in changes to medications prescribed, and reduced the prevalence of potentially inappropriate medication use.

Methods
=======

Study population and setting
----------------------------

We conducted a prospective observational cohort study of four RACFs in Queensland, Australia, that currently have regular access to geriatric consultations via VC. The participating facilities were the first four to be supported by the geriatrician service operating out of the Centre for Research in Geriatric Medicine. We were able to record the information for 153 patients assessed by four geriatricians over the research timeframe.

Data collection
---------------

At participating facilities, geriatrician-supported CGA is encouraged within 4--12 weeks of admission. All residents are offered CGA at entry into the participating RACF. However, uptake is determined by referral from the treating general practitioners. The CGA is conducted using a structured protocol based on the interRAI (Resident Assessment Instrument) Long-Term Facility assessment system, administered by a senior registered nurse. The assessment includes a comprehensive diagnosis list, justification of all medications documented, functional profile, cognitive assessment confirming the presence or absence of cognitive and mood disorders, recommendations for prevention and management, and advanced care planning. Observations made by the nurse are entered into a clinical decision support system, which generates a draft resident health care profile and care plan. The clinical decision support system is mounted on a web-based platform to permit review and comment by a specialist geriatrician. interRAI is a not-for-profit research consortium with international collaboration from more than 30 countries that aims to improve the quality of life of vulnerable persons through a unified comprehensive assessment system.

Ideally, 1--4 weeks following admission to the facility, residents who have been referred to a geriatrician by the GP are assessed via video-consultation by the specialist. The geriatrician is able to speak with the resident as well as attending RACF staff and resident's family members if present. Recommendations to the GP and RACF are made, as necessary, regarding the resident's care plan following the consultation. CGA is also offered to existing residents on an "as needs" basis. A formal functional profile is prepared, and a report is generated recording the recommendations made by the geriatrician. Data for this study were retrieved from these sources over an 18-month period from January 2013 to August 2014. Ethics approval was obtained from the University of Queensland Medical Research Ethics Committee. All patients or their substitute decision-maker gave informed consent for participation.

Key measures
------------

The primary outcome measure was the appropriateness of prescribing. A high-risk medications list was created based on those recognized by the American Geriatric Society 2012 Beers Criteria,[@b11-cia-10-1043] the McLeod criteria,[@b12-cia-10-1043] the Laroche criteria,[@b13-cia-10-1043] the PRISCUS criteria,[@b14-cia-10-1043] and the Norwegian General Practice criteria[@b15-cia-10-1043] ([Table 1](#t1-cia-10-1043){ref-type="table"}). These criteria consider a medication as high risk when it has a tendency to cause adverse drug events and drug toxicity in older adults due to its pharmacological properties and the physiologic changes of aging. For our study, we defined high-risk medications as those that are listed on any one of these criteria. We excluded medications not available in Australia. Polypharmacy status was categorized into three groups based on the number of medications prescribed: non-polypharmacy (0--4 medications), polypharmacy (5--9 medications), and hyper-polypharmacy (≥10 medications).[@b16-cia-10-1043] Complementary and as-required medications were excluded. Three levels of change on current prescription were defined as drug stopped, dose altered, and new drug started.

Statistical analysis
--------------------

The Statistical Package for Social Science 21.0 (IBM SPSS Statistics 21. Ink) was used for statistical analysis. Categorical variables were summarized using proportions and continuous variables using mean, standard deviation (SD), and range. In univariate analysis, the differences in the distribution of variables between patients with or without high-risk medications were compared using the chi-squared test for categorical variables, and nonparametric or parametric comparison of means for continuous variables, depending on the distribution of the data. Tests of significance were two-tailed, using a significance level of *P*≤0.05.

Results
=======

Over the course of the study, 153 patients were assessed by the four participating geriatricians across four facilities. Demographics and clinical characteristics of the study population are presented in [Table 2](#t2-cia-10-1043){ref-type="table"}. The mean (± SD) patient age was 83.0 (±8.1) years and 64.1% were female. The median length of stay in the facility at the time of assessment was 488 days (range 6--3,213 days). Twenty-four percent of patients were assessed within 12 weeks of admission to the facility. Patients had multiple comorbidities (mean 6), including dementia diagnosed in 67.3%, depression in 46.4%, and delirium in 11.7%. Other prevalent comorbidities were hypertension (35.9%), diabetes (20.9%), heart diseases (13.7%), and respiratory diseases (11.1%). Patients were prescribed a mean (± SD) of 9.6 (±4.2) regular medications. Polypharmacy (≥5 medications) was seen in 91% (n=139) residents, half of whom (n=69) were exposed to hyper-polypharmacy (≥10 medications).

Of all medications prescribed (n=1,469), the geriatrician recommended withdrawal of 9.8% (n=145) and dose alteration for 3.5% (n=51) medications. Medications were stopped because of adverse effects (n=66), no clear indication/medication burden (n=63), and disease cured (n=16). Similarly, the medication dose was altered because of adverse effects and other factors (n=36), changed to "as required" (n=5), and ineffective dose (n=10). New medications were initiated in 47.7% (n=73) patients ([Table 3](#t3-cia-10-1043){ref-type="table"}). High-risk medications prescribed (10.3%; n=151) and intervention by geriatricians are listed by drug classes in [Table 4](#t4-cia-10-1043){ref-type="table"}. At least one high-risk medication was prescribed to 58.2% (n=89) patients. The univariate analysis showed that the length of stay was the only variable significantly associated with patients having at least one high-risk medication ([Table 5](#t5-cia-10-1043){ref-type="table"}). Of the high-risk medications, the geriatrician ceased 17.2% (n=26) medications and altered the dose in 2.6% (n=4). High-risk medications stopped were analgesics (n=6), antispasmodics (n=5), sedative and hypnotics (n=5), antipsychotics (n=3), antiarrhythmic (n=3), antihypertensive (n=2), gastrointestinal medications (n=1), and antibiotics (n=1). The dose was altered for antiarrhythmic (n=2), antidepressants (n=1), and sedative and hypnotics (n=1).

Discussion
==========

To our knowledge, this is the first study of a geriatrician intervention where the medication advice for residents at long-term residential care facilities was specifically assessed via video-consultation. We found moderate levels of high-risk medications prescribed to residents in RACFs. Geriatricians made relatively few changes. This suggests that either the prescription of these medications was appropriate or other factors influenced the decision not to adjust medications.

The aim of defining high-risk medication use is to focus on a group of medications for which there is common consensus about potential inappropriateness. In principle, the high-risk medications prescribed to RACF residents in our study should not have been started or continued except under certain conditions; for example, amiodarone, a high-risk medication used in older people, is a therapy that may be indicated to treat supraventricular arrhythmias effectively in patients with heart failure;[@b17-cia-10-1043] and benzodiazepines, that may increase the risk of mental decline, delirium, falls, and fractures in older adults, may be appropriate for treating seizures, certain sleep disorders, and anxiety disorders.[@b11-cia-10-1043] The reluctance on the part of the geriatrician in adjusting/stopping many of these high-risk medications might suggest that prescription of some of these medications was appropriate. It is also possible that patients' (or primary care medical practitioners') strong belief in their medications might impact on an otherwise appropriate reduction in the number of medications taken, but this was not specifically explored in our study. In addition to these patient-related factors, there might be some prescriber-related factors that hinder medication adjustment, such as involvement of several prescribers, the use of preventive medication, and evidence-based medicine guidelines that often induce polypharmacy, uncertainties of precipitating disease relapse or drug withdrawal syndromes, and lack of risk/benefit information for the frail older residents.[@b18-cia-10-1043]

Interventions for appropriate prescribing in older people such as education, medication reviews, computerized support systems, and interdisciplinary team review have a positive impact on prescribing.[@b10-cia-10-1043] Yet, evidence for effective interventions to improve care in residential care settings is limited. A study by Crotty et al suggested that case conferences help an outreach geriatrician team to optimize medication management.[@b7-cia-10-1043] They describe the use of multidisciplinary case conference meetings to review medication in RACFs with significant improvement in medication appropriateness in the intervention group. There is conflicting evidence, however, concerning the efficacy of case conference medication reviews. One study using case conferencing to review the prescription and use of medications for community-dwelling older adults was unsuccessful in demonstrating the change in inappropriate use of medications.[@b19-cia-10-1043] A similar study in residential care facilities was unsuccessful in establishing changes in the number of medications.[@b20-cia-10-1043] Other approaches to optimize prescribing in frail older people might be the integration of a pharmacist in a team to make a collaborative approach on the quality of prescribing. Studies from inpatient settings suggest that the addition of a pharmacist to health care teams could lead to major reductions in morbidity and improved patient outcomes.[@b21-cia-10-1043],[@b22-cia-10-1043] Another study on older patients transferring from hospital to a long-term care facility showed that adding a pharmacist transition coordinator on evidence-based medication management and health outcomes could improve the aspects of inappropriate use of medications.[@b23-cia-10-1043]

Optimizing prescribing requires appropriate ways to taper or withdraw high-risk medications in older adults. Available explicit and implicit criteria for appropriate prescribing encompass medications that have been validated in, and applied to, robust, healthy populations aged 65 and older. Therefore, these approaches may not be applicable to the more frail and multimorbid oldest old who reside in RACFs.[@b24-cia-10-1043] Most attention has been paid to the development of guidelines on how to initiate medications, but there are limited studies on the most effective way to cease medications.[@b25-cia-10-1043],[@b26-cia-10-1043] Barriers to cease medications include time constraints on medical practitioners. This had led some to advocate that there should be some systematic approaches to follow in ceasing medications.[@b27-cia-10-1043],[@b28-cia-10-1043] In responding to polypharmacy and minimizing high-risk medications, there appears a need for a practical algorithm that helps clinicians identify and discontinue potentially inappropriate high-risk medications using a systematic approach. This algorithm should signify a range of different clinical scenarios in relation to high-risk medications and offer an evidence-based approach to identify and, if appropriate, discontinue such medications and/or suggesting alternative treatments when required.

Our study has several limitations. Although, combining five different explicit criteria gives us an opportunity to extract a comprehensive list of high-risk medications, this list is not meant to regulate practice in a manner that surpasses the clinical judgment and the assessment of a prescriber. Also, because of our definition of high-risk medications as a list of drugs, the further domains of inappropriate prescribing such as underuse of medications and drug--drug interaction might be missed. Any adverse health events occurring among the residents using high-risk medications were also not investigated in our study. Considering the small sample size of 153 patients, the study results may not be representative of larger sample size in different nursing home settings.

Conclusion
==========

In this study of 153 residents of four RACFs, we found a moderate prevalence of potentially inappropriate high-risk medications. However, geriatricians made relatively few changes, suggesting either that, on balance, prescription of these medications was appropriate or, because of other factors, there was a reluctance to adjust medications. Further research, including a broader survey, is required to understand these dynamics. A structured medication review using an algorithm for withdrawing medications of high disutility might help optimize medication prescribing in frail older people.
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High-risk medications list

  Medication                                                                             ATC codes   Main concerns                                                                                                                                                                                                                                                                                                                                    References
  -------------------------------------------------------------------------------------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------
  **Analgesics, anti-inflammatory**                                                                                                                                                                                                                                                                                                                                                                                                                   
  **NSAID**                                                                                                                                                                                                                                                                                                                                                                                                                                           
    Aspirin \>325 mg/day                                                                 N02BA01     -- Very high risk of gastrointestinal hemorrhage, ulceration, or perforation, which may be fatal                                                                                                                                                                                                                                                 [@b11-cia-10-1043]
    Diclofenac                                                                           M01AB05     -- Risk of renal toxicity especially in patients with preexisting chronic                                                                                                                                                                                                                                                                        [@b11-cia-10-1043]
    Ketoprofen                                                                           M01AE03     kidney disease                                                                                                                                                                                                                                                                                                                                   [@b11-cia-10-1043],[@b14-cia-10-1043]
    Ketorolac                                                                            M01AB15                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b12-cia-10-1043]
    Mefenamic acid                                                                       M01AG01     -- Risk of fluid retention and fluid overload leading to decompensated                                                                                                                                                                                                                                                                           [@b11-cia-10-1043],[@b12-cia-10-1043]
    Meloxicam                                                                            M01AC06     heart failure in patients with underlying cardiac dysfunction                                                                                                                                                                                                                                                                                    [@b11-cia-10-1043],[@b14-cia-10-1043]
    Naproxen                                                                             M01AE02                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043]
    Piroxicam                                                                            M01AC01     -- Indomethacin may also have CNS side effects                                                                                                                                                                                                                                                                                                   [@b11-cia-10-1043],[@b12-cia-10-1043],[@b14-cia-10-1043]
    Indomethacin                                                                         M01AB01                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043]--[@b14-cia-10-1043]
    Etoricoxib                                                                           M01AH05                                                                                                                                                                                                                                                                                                                                                      [@b14-cia-10-1043]
    Ibuprofen                                                                            M01AE01                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043]
   **Opioid analgesics**                                                                                                                                                                                                                                                                                                                                                                                                                              
    Pethidine                                                                            N02AB02     -- Elevated risk of delirium and falls                                                                                                                                                                                                                                                                                                           [@b11-cia-10-1043],[@b12-cia-10-1043],[@b14-cia-10-1043]
  -- Risk of neurotoxicity                                                                                                                                                                                                                                                                                                                                                                                                                            
  **Antiarrhythmic**                                                                                                                                                                                                                                                                                                                                                                                                                                  
   Amiodarone                                                                            C01BD01     -- Predisposition to bradycardia and heart block                                                                                                                                                                                                                                                                                                 [@b11-cia-10-1043]
   Flecainide                                                                            C01BC04     -- Pro-arrhythmic effects                                                                                                                                                                                                                                                                                                                        [@b11-cia-10-1043],[@b14-cia-10-1043]
   Sotalol                                                                               C07AA07     -- Pro-arrhythmic effects                                                                                                                                                                                                                                                                                                                        [@b11-cia-10-1043],[@b14-cia-10-1043],[@b15-cia-10-1043]
   Disopyramide                                                                          C01BA03     -- Potent negative inotropic effects predisposing to heart failure                                                                                                                                                                                                                                                                               [@b11-cia-10-1043]--[@b13-cia-10-1043]
  -- Anticholinergic activity                                                                                                                                                                                                                                                                                                                                                                                                                         
   Digoxin \>0.125 mg/day                                                                C01AA05     -- Risk of toxicity especially in presence of renal insufficiency                                                                                                                                                                                                                                                                                [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
   Nifedipine                                                                            C08CA05     -- Potential for postural hypotension                                                                                                                                                                                                                                                                                                            [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
  -- Short-acting formulations associated with increased mortality in elderly patients                                                                                                                                                                                                                                                                                                                                                                
   Spironolactone \>25 mg/day                                                            C03DA01     -- Risk of hyperkalemia                                                                                                                                                                                                                                                                                                                          [@b11-cia-10-1043]
   Diltiazem                                                                             C08DB01     -- Potential to promote fluid retention and exacerbate heart failure                                                                                                                                                                                                                                                                             [@b11-cia-10-1043]
   Verapamil                                                                             C08DA01                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043]
  **Antibiotics**                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Nitrofurantoin                                                                        J01XE01     -- Long-term use associated with pulmonary side effects, renal impairment, liver damage                                                                                                                                                                                                                                                          [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
  **Anticholinergics**                                                                                                                                                                                                                                                                                                                                                                                                                                
   **Antihistamines**                                                                                                                                                                                                                                                                                                                                                                                                                                 
    Chlorpheniramine                                                                     R06AB02     -- Risk of anticholinergic effect: constipation, dry mouth, visual disturbance, bladder dysfunction                                                                                                                                                                                                                                              [@b11-cia-10-1043],[@b14-cia-10-1043]
    Cyproheptadine                                                                       R06AX02                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043]
    Dexchlorpheniramine                                                                  R06AB02     -- Clearance reduced with advanced age                                                                                                                                                                                                                                                                                                           [@b11-cia-10-1043],[@b13-cia-10-1043],[@b15-cia-10-1043]
    Diphenhydramine                                                                      R06AA02     -- Increased risk of confusion and sedation, impaired cognitive performance                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Doxylamine                                                                           R06AA09                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Promethazine                                                                         R06AD02                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b15-cia-10-1043]
   **Antiparkinson agents**                                                                                                                                                                                                                                                                                                                                                                                                                           
    Benztropine                                                                          N04AC01     -- Risk of anticholinergic side effects                                                                                                                                                                                                                                                                                                          [@b11-cia-10-1043]
  -- Not recommended for prevention of extrapyramidal symptoms due to antipsychotics                                                                                                                                                                                                                                                                                                                                                                  
   **Antispasmodics**                                                                                                                                                                                                                                                                                                                                                                                                                                 
    Propantheline                                                                        A03AB05     -- Highly anticholinergic, uncertain effectiveness                                                                                                                                                                                                                                                                                               [@b11-cia-10-1043]
    Oxybutynin                                                                           G04BD04     -- Anticholinergic side effects                                                                                                                                                                                                                                                                                                                  [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Solifenacin                                                                          G04BD08     -- ECG changes (prolonged QT)                                                                                                                                                                                                                                                                                                                    [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Tolterodine (non-sustained release)                                                  G04BD07                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
  **Antithrombotics**                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Dipyridamole (short-acting)                                                           B01AC07     -- Risk of orthostatic hypotension                                                                                                                                                                                                                                                                                                               [@b11-cia-10-1043]--[@b13-cia-10-1043]
   Warfarin                                                                              B01AA03     -- Increased risk of bleeding                                                                                                                                                                                                                                                                                                                    [@b11-cia-10-1043],[@b14-cia-10-1043]
   Prasugrel                                                                             B01AC22                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b14-cia-10-1043]
   Ticlopidine                                                                           B01AC05                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b14-cia-10-1043]
  **Antidepressants**                                                                                                                                                                                                                                                                                                                                                                                                                                 
   **TCA**                                                                                                                                                                                                                                                                                                                                                                                                                                            
    Amitriptyline                                                                        N06AA09     -- Peripheral anticholinergic side effects (eg, constipation, dry mouth, orthostatic hypotension, and cardiac arrhythmia)                                                                                                                                                                                                                        [@b11-cia-10-1043]--[@b15-cia-10-1043]
    Clomipramine                                                                         N06AA04                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043]--[@b15-cia-10-1043]
    Doxepin (\>6 mg)                                                                     N06AA12     -- Central anticholinergic side effects (drowsiness, inner unrest, confusion, other types of delirium)                                                                                                                                                                                                                                           [@b11-cia-10-1043],[@b13-cia-10-1043]--[@b15-cia-10-1043]
    Imipramine                                                                           N06AA02     -- Cognitive impairment                                                                                                                                                                                                                                                                                                                          [@b11-cia-10-1043]--[@b14-cia-10-1043]
    Nortriptyline                                                                        N06AA10     -- Increased risk of falls                                                                                                                                                                                                                                                                                                                       [@b11-cia-10-1043]
   **SSRI**                                                                                                                                                                                                                                                                                                                                                                                                                                           
    Fluoxetine (daily use)                                                               N06AB03     -- CNS side effects (nausea, insomnia, dizziness, confusion)                                                                                                                                                                                                                                                                                     [@b11-cia-10-1043],[@b14-cia-10-1043],[@b15-cia-10-1043]
  -- Hyponatremia                                                                                                                                                                                                                                                                                                                                                                                                                                     
    Paroxetine                                                                           N06AB05     -- Confusion and other types of delirium                                                                                                                                                                                                                                                                                                         [@b11-cia-10-1043]
  -- Cognitive impairment                                                                                                                                                                                                                                                                                                                                                                                                                             
   **MAO inhibitors**                                                                                                                                                                                                                                                                                                                                                                                                                                 
    Tranylcypromine                                                                      N06AF04     -- Hypertensive crises                                                                                                                                                                                                                                                                                                                           [@b11-cia-10-1043],[@b14-cia-10-1043]
  -- Cerebral hemorrhage                                                                                                                                                                                                                                                                                                                                                                                                                              
  -- Malignant hyperthermia                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Antiemetic drugs**                                                                                                                                                                                                                                                                                                                                                                                                                                
   Trimethobenzamide                                                                     NA          -- Can cause extrapyramidal adverse effects                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043]
  **Antiepileptic drugs (AEDs)**                                                                                                                                                                                                                                                                                                                                                                                                                      
   Phenobarbitone                                                                        N03AA02     -- Sedation                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b14-cia-10-1043]
  -- Paradoxical excitation                                                                                                                                                                                                                                                                                                                                                                                                                           
  -- Highly addictive                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Antihypertensive agents**                                                                                                                                                                                                                                                                                                                                                                                                                         
   Clonidine                                                                             C02AC01     -- Hypotension (orthostatic), bradycardia, syncope                                                                                                                                                                                                                                                                                               [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
   Methyldopa                                                                            C01AB01     -- CNS side effects: sedation, cognitive impairment                                                                                                                                                                                                                                                                                              [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
   Moxonidine                                                                            C02AC05     -- H ypotension (orthostatic)                                                                                                                                                                                                                                                                                                                    [@b13-cia-10-1043]
  -- Bradycardia                                                                                                                                                                                                                                                                                                                                                                                                                                      
  -- Sedation                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Nifedipine                                                                            C08CA05     -- Short-acting nifedipine associated with increased risk of myocardial infarction, increased mortality in elderly patients                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043]
   Prazosin                                                                              C02CA01     -- Hypotension                                                                                                                                                                                                                                                                                                                                   [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
   Terazosin                                                                             G04CA03     -- Dry mouth                                                                                                                                                                                                                                                                                                                                     [@b11-cia-10-1043],[@b14-cia-10-1043]
  -- Urinary incontinence/impaired micturition                                                                                                                                                                                                                                                                                                                                                                                                        
  -- Increased risk of cerebrovascular and cardiovascular disease                                                                                                                                                                                                                                                                                                                                                                                     
  **Antipsychotics (neuroleptic drugs)**                                                                                                                                                                                                                                                                                                                                                                                                              
   First-generation (conventional) agents                                                                                                                                                                                                                                                                                                                                                                                                             
    Chlorpromazine                                                                       N05AA01     -- Anticholinergic and extrapyramidal side effects                                                                                                                                                                                                                                                                                               [@b11-cia-10-1043]--[@b13-cia-10-1043],[@b15-cia-10-1043]
    Fluphenazine                                                                         N05AB02     -- Parkinsonism                                                                                                                                                                                                                                                                                                                                  [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Haloperidol (\>2 mg)                                                                 N05AD01     -- H ypotonia                                                                                                                                                                                                                                                                                                                                    [@b11-cia-10-1043],[@b14-cia-10-1043]
    Promazine                                                                            N05AA03     -- S edation and risk of falls                                                                                                                                                                                                                                                                                                                   [@b11-cia-10-1043],[@b13-cia-10-1043]
    Trifluoperazine                                                                      N05AB06     -- Increased mortality in patients with dementia                                                                                                                                                                                                                                                                                                 [@b11-cia-10-1043]
    Prochlorperazine                                                                     N05AB04                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043]--[@b15-cia-10-1043]
   Second-generation (atypical) agents                                                                                                                                                                                                                                                                                                                                                                                                                
    Aripiprazole                                                                         N05AX12     -- Fewer extrapyramidal side effects                                                                                                                                                                                                                                                                                                             [@b11-cia-10-1043]
    Asenapine                                                                            N05AH05     -- Clozapine: increased risk of agranulocytosis and myocarditis                                                                                                                                                                                                                                                                                  [@b11-cia-10-1043]
    Clozapine                                                                            N05AH02                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Olanzapine (\>10 mg)                                                                 N05AH03                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043]--[@b15-cia-10-1043]
  **Muscle relaxants**                                                                                                                                                                                                                                                                                                                                                                                                                                
   Baclofen                                                                              M03BX01     -- CNS side effects: amnesia, confusion, falls                                                                                                                                                                                                                                                                                                   [@b13-cia-10-1043],[@b14-cia-10-1043]
   Solifenacin                                                                           G04BD08     -- Anticholinergic side effects: constipation, dry mouth, CNS side effects                                                                                                                                                                                                                                                                       [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
   Orphenadrine                                                                          N04AB02     -- More sedation and anticholinergic side effects than safer alternatives                                                                                                                                                                                                                                                                        [@b11-cia-10-1043]
  **Sedative and hypnotics**                                                                                                                                                                                                                                                                                                                                                                                                                          
   Long-acting benzodiazepines                                                                                                                                                                                                                                                                                                                                                                                                                        
    Clonazepam                                                                           N03AE01     In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls (muscle-relaxing effect, prolonged sedation) with risk of hip fracture, depression, psychiatric reactions (can cause paradoxical reactions, eg, agitation, irritability, hallucinations, and psychosis) and motor vehicle accidents in older adults   [@b11-cia-10-1043]
    Diazepam                                                                             N05BA01                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043]--[@b15-cia-10-1043]
    Bromazepam                                                                           N05BA08                                                                                                                                                                                                                                                                                                                                                      [@b13-cia-10-1043],[@b14-cia-10-1043]
    Clobazam                                                                             N05BA09                                                                                                                                                                                                                                                                                                                                                      [@b13-cia-10-1043]
    Nitrazepam                                                                           N05CD02                                                                                                                                                                                                                                                                                                                                                      [@b13-cia-10-1043]--[@b15-cia-10-1043]
    Flunitrazepam                                                                        N05CD03                                                                                                                                                                                                                                                                                                                                                      [@b13-cia-10-1043]--[@b15-cia-10-1043]
   Short- and intermediate-acting benzodiazepines                                                                                                                                                                                                                                                                                                                                                                                                     
    Alprazolam                                                                           N05BA12                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Lorazepam                                                                            N05BA06                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Oxazepam                                                                             N05BA04                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043]--[@b15-cia-10-1043]
    Temazepam                                                                            N05CD07                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Triazolam                                                                            N05CD05                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043]--[@b14-cia-10-1043]
   Non-benzodiazepine hypnotics                                                                                                                                                                                                                                                                                                                                                                                                                       [@b11-cia-10-1043]--[@b14-cia-10-1043]
    Zolpidem                                                                             N05CF02                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b13-cia-10-1043],[@b14-cia-10-1043]
    Zopiclone                                                                            N05CF01                                                                                                                                                                                                                                                                                                                                                      [@b13-cia-10-1043]--[@b15-cia-10-1043]
    Chloral hydrate                                                                      N05CC01                                                                                                                                                                                                                                                                                                                                                      [@b11-cia-10-1043],[@b14-cia-10-1043]
  **Others**                                                                                                                                                                                                                                                                                                                                                                                                                                          
   Theophylline                                                                          R03DA02     -- Risk of arrhythmias                                                                                                                                                                                                                                                                                                                           [@b11-cia-10-1043],[@b15-cia-10-1043]
  -- No proof of efficacy in COPD                                                                                                                                                                                                                                                                                                                                                                                                                     
   Glipizide                                                                             A10BB07     -- Long half-life leading to possible prolonged hypoglycemia                                                                                                                                                                                                                                                                                     [@b13-cia-10-1043]
   Cimetidine                                                                            A02BA01     -- Confusion                                                                                                                                                                                                                                                                                                                                     [@b11-cia-10-1043]--[@b13-cia-10-1043]
  -- More interactions than other H2 antagonists                                                                                                                                                                                                                                                                                                                                                                                                      
   Diphenoxylate                                                                         A07DA01     -- No proof of efficacy                                                                                                                                                                                                                                                                                                                          [@b12-cia-10-1043],[@b13-cia-10-1043]
  -- Blocks the muscarinic receptors                                                                                                                                                                                                                                                                                                                                                                                                                  

**Abbreviations:** ATC, anatomical therapeutic chemical; COPD, chronic obstructive pulmonary disease; CNS, central nervous system; ECG, electrocardiogram; MAO, monoamine oxidase; NSAID, non-steroidal anti-inflammatory drugs; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants.

###### 

Demographic and clinical characteristics of study population

  Characteristics                                                               Total, N=153
  ----------------------------------------------------------------------------- ----------------
  Age, years                                                                    
   Mean ± SD                                                                    83.0±8.1
   Median                                                                       83
  Females, n (%)                                                                98 (64.1)
  Length of stay at the time of assessment: median length of stay, days (IQR)   488 (6--3,213)
  Marital status (%)                                                            
   Married                                                                      50 (32.6)
   Widowed                                                                      73 (47.7)
   Separated/divorced                                                           19 (12.4)
   Never married                                                                11 (7.1)
  Comorbidities (%)                                                             
   Dementia                                                                     103 (67.3)
   Delirium                                                                     18 (11.7)
   Depression                                                                   71 (46.4)
   Under nutrition                                                              49 (32.0)
   COPD/asthma                                                                  17 (11.1)
   Hypertension                                                                 55 (35.9)
   Diabetes                                                                     32 (20.9)
   Ischemic heart disease                                                       21 (13.7)
  Prescription medications                                                      
   Total number of prescribed medications                                       1,469
   Mean ± SD                                                                    9.6±4.2
  Polypharmacy categories (%)                                                   
   0--4 medications (non-polypharmacy)                                          14 (9.2)
   5--9 medications (polypharmacy)                                              70 (45.8)
   ≥10 medications (hyper-polypharmacy)                                         69 (45.1)

**Abbreviations:** COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SD, standard deviation.

###### 

Outcomes of geriatrician intervention

  Interventions                     No of medications                              Reasons
  --------------------------------- ---------------------------------------------- -------------------------------------------------------------
  Drug stopped (145 \[9.8%\])       66                                             Adverse effects
  63                                No clear indication/medication burden          
  16                                Disease cured or quiescent                     
  Dose altered (51 \[3.5%\])        36                                             Dose reduced (because of adverse effects and other factors)
  10                                Dose increased (because of ineffective dose)   
  5                                 Changed to "as required"                       
  New drug started (102 \[6.9%\])   58                                             Untreated morbidity
  23                                Better alternative to present therapy          
  21                                Symptom relief                                 

**Notes:** Total medication prescribed: 1,469; total high-risk medications prescribed: 151 (10.3%).

###### 

High-risk medication prescribed and geriatrician intervention

  System/therapeutic category/medications   High-risk medications prescribed, N (%)   Result of geriatrician intervention
  ----------------------------------------- ----------------------------------------- -------------------------------------
  Central nervous system medications        80 (52.9)                                 
   Antidepressants                          10 (6.6)                                  DA -- 1
   Antipsychotics                           21 (13.9)                                 DS -- 3
  NDS -- 1                                                                            
   Sedative and hypnotics                   49 (32.4)                                 DS -- 5
  DA -- 1                                                                             
  NDS -- 2                                                                            
  Cardiovascular system medications         21 (13.9)                                 
   Antiarrhythmic                           12 (7.9)                                  DS -- 3
  DA -- 2                                                                             
  NDS -- 1                                                                            
   Antihypertensive                         9 (5.9)                                   DS -- 2
   Gastrointestinal                         6 (3.9)                                   DS -- 1
   Antihistamines                           5 (3.3)                                   
   Antithrombotic                           22 (14.5)                                 
   Antiparkinson agents                     1 (0.6)                                   
   Antispasmodics                           5 (3.3)                                   DS -- 5
   Analgesics                               9 (5.9)                                   DS -- 6
   Antibiotics                              2 (1.3)                                   DS -- 1
   Total                                    151 (100)                                 DA -- 4
  DS -- 26                                                                            
  NDS -- 4                                                                            

**Abbreviations:** DA, dose altered; DS, drug stopped; NDS, new drug started.

###### 

Univariate analysis of variables influencing the use of high-risk medications

  Characteristics                                     Patients              *P*-value             
  --------------------------------------------------- --------------------- --------------------- -------
  Socio-demographic                                                                               
   Age                                                83.55±8.5             82.67±7.8             0.513
   Sex (female)                                       44 (68.8)             54 (60.7)             0.304
  Clinical                                                                                        
   Length of stay                                     303 (70.75--780.50)   630 (100--1,022.50)   0.044
   Assessment status (within 12 weeks of admission)   18 (28.1)             19 (21.3)             0.334
   Polypharmacy (\>4 medications)                     57 (89.1)             82 (92.1)             0.516
  Comorbid conditions                                                                             
   Delirium                                           7 (10.9)              11 (12.4)             0.788
   Dementia                                           44 (68.8)             59 (66.3)             0.749
   Depression                                         27 (42.2)             44 (49.4)             0.375
   Under nutrition                                    24 (37.5)             25 (28.1)             0.218

**Note:** Values represent frequency (% of n).
